Effectiveness of Folic Acid Supplementation in Acute Watery Diarrhea Among Children Under 5 Years of Age

Sponsor
King Edward Medical University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04782037
Collaborator
(none)
324
1
2
20.3
16

Study Details

Study Description

Brief Summary

Folic acid is a palatable and easily available drug with no serious adverse effects. L-methylfolate is its biologically activated form and is preferred because of its direct availability for certain metabolic processes. As there is no specific and safe drug available that may help in decreasing the duration of diarrhea, purging rate or consistency of stools; and having known the theoretical benefits of folic acid in this regard, it would be appropriate to assess the effectiveness of L-methylfolate among children with diarrhea.

Condition or Disease Intervention/Treatment Phase
  • Drug: L-Methylfolate Calcium
Phase 4

Detailed Description

After approval from the Institutional Review Board of King Edward Medical University, Mayo Hospital, Lahore, all children diagnosed with acute watery diarrhea as per operational definition fulfilling the inclusion criteria, presenting to the Department of Pediatrics, Mayo Hospital, will be enrolled in this study.

Informed written consent will be taken from the parents/guardians of all participants. A detailed history and examination of each subject would be done by an investigator at presentation.

Patients will be randomized in two groups - A and B by lottery method. There will be 162 patients in each group. The treatment regimen that includes breast feeding, nutritional advice, rehydration plan; ORT by low osmolar ORS or intravenous rehydration (if required) and zinc sulphate will be given according to the WHO guidelines to all patients of both groups. Children under 1 year of age in group A will receive 3 drops (90mcg) of L-methylfolate calcium) while those older than 1 year of age will be given 5 drops (150mcg). Subjects in Group B will receive equal amount of distilled water as placebo (i.e. 3 drops to <1yr age and 5 drops to >1 yr. Frequency and grades of loose stools in both groups will be assessed daily and written down on a predesigned proforma.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
324 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Effectiveness of Folic Acid Supplementation in Acute Watery Diarrhea Among Children Under 5 Years of Age
Actual Study Start Date :
Oct 21, 2020
Anticipated Primary Completion Date :
Jul 1, 2022
Anticipated Study Completion Date :
Jul 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: L-methylfolate supplementation

Children under 1 year of age in group A will receive 3 drops (90mcg) of L-methylfolate calcium) while those older than 1 year of age will be given 5 drops (150mcg) daily fior 5 days

Drug: L-Methylfolate Calcium
Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.

Placebo Comparator: distilled water

Subjects in Group B will receive equal amount of distilled water as placebo (i.e. 3 drops to <1yr age and 5 drops to >1 yr.

Drug: L-Methylfolate Calcium
Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.

Outcome Measures

Primary Outcome Measures

  1. Changing the frequency of stools [5 days]

    L-methylfolate supplementation is effective in changing the frequency of stools. It will be measured in episodes per day

  2. Effectiveness in improving grades of diarrhea [5 days]

    L-methylfolate supplementation is effective in changing grades of diarrhea. WHO grades will be taken as reference

  3. Effectiveness in changing duration of diarrhea [5 days]

    L-methylfolate supplementation is effective in changing duration of diarrhea in days.

Eligibility Criteria

Criteria

Ages Eligible for Study:
2 Months to 5 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Children aged 2months- 5 years

  • Both genders

  • Acute watery diarrhea as per operational definition

  • Diarrhea of less than 7-day duration

Exclusion Criteria:
  • Severely malnourished children <3 SD

  • Bloody diarrhea

  • Prolonged (7-14 days duration), persistent (>14 days duration) or chronic diarrhea (>4weeks duration)

  • Those who received folic acid within the last 14 days

  • Hospital-acquired diarrhea (diarrhea occurring after 48hrs of stay in hospital)

  • Antibiotic-associated diarrhea.

  • Presence of other co morbid conditions like pneumonia, sepsis, meningitis, etc.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mayo hospital Lahore Punjab Pakistan 56000

Sponsors and Collaborators

  • King Edward Medical University

Investigators

  • Principal Investigator: MUHAMMAD Haroon HAMID, MBBS,FCPS, CHAIRMAN PEDIATRIC MEDICINE, MAYO HOSPITAL
  • Principal Investigator: Sadia shabir, MBBS, FCPS, ASSISTANT PROFESSOR, PEDIATRIC MEDICINE UNIT 1, MAYO HOSPITAL

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
rafia Jamil, Post Graduate Resident (MD Pediatric Medicine), King Edward Medical University
ClinicalTrials.gov Identifier:
NCT04782037
Other Study ID Numbers:
  • 321/RC/KEMU
First Posted:
Mar 4, 2021
Last Update Posted:
May 19, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by rafia Jamil, Post Graduate Resident (MD Pediatric Medicine), King Edward Medical University
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 19, 2022